December,2021- Arena Pharmaceuticals, Inc. and Pfizer Inc. announced that they had reached a final agreement whereby Pfizer will purchase Arena, a clinical stage business creating novel therapeutic treatments for the management of several immuno-inflammatory illnesses. Pfizer will purchase all of Arena's outstanding shares under the terms of the agreement for $100 per share in an all-cash deal, for a total equity value of roughly $6.7 billion. Both firms' boards of directors have overwhelmingly approved the deal.
May,2019- In order to promote clinical research in pulmonary hypertension (PH), with an emphasis on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), Bayer U.S. announced the creation of the Pulmonary Hypertension Accelerated Bayer (PHAB) Awards. Over the course of a two-year cycle, the initiative will provide grants totaling up to $1 million.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 3318
Published Date: Jan 03, 2024
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing prevalence of hypertension, progressive government policies, Adoption of precision medicine are some of the major growth drivers for the thiazide diuretics market.
The market size of thiazide diuretics is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2024-2036.
The major players in the market are Pfizer Inc., Merck & Co., Inc., Sanofi, Bayer AG, Centaur Pharmaceuticals Private Limited, Validus Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Novartis Pharmaceuticals Corporation, Boehringer Ingelheim International GmbH, Cipla Inc. and others.
The hypertension segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.